277 related articles for article (PubMed ID: 33327291)
21. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
22. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
24. Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH.
Patel AH; Pathak GN; Chen A; Greenberg P; Mazzaferro N; Patel A; Mallangada N; Minacapelli CD; Catalano K; Suthar H; Rustgi VK
Ann Hepatol; 2024; 29(4):101510. PubMed ID: 38714224
[TBL] [Abstract][Full Text] [Related]
25. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Avillach P; Egger P; Dhalwani NN; Kendrick S; Celis-Morales C; Waterworth DM; Alazawi W; Sattar N
BMJ; 2019 Oct; 367():l5367. PubMed ID: 31594780
[TBL] [Abstract][Full Text] [Related]
26. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
[TBL] [Abstract][Full Text] [Related]
29. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
Nguyen AL; Park H; Nguyen P; Sheen E; Kim YA; Nguyen MH
Dig Dis Sci; 2019 Mar; 64(3):698-707. PubMed ID: 30327963
[TBL] [Abstract][Full Text] [Related]
30. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
31. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
Golabi P; Owrangi S; Younossi ZM
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
[TBL] [Abstract][Full Text] [Related]
32. Societal costs and survival of patients with biopsy-verified non-alcoholic steatohepatitis: Danish nationwide register-based study.
Rudolfsen JH; Gluud LL; Grønbæk H; Jensen MK; Vyberg M; Olsen J; Bo Poulsen P; Hovelsø N; Gregersen NT; Thomsen AB; Jepsen P
Ann Hepatol; 2024; 29(3):101285. PubMed ID: 38272183
[TBL] [Abstract][Full Text] [Related]
33. Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Osganian SA; Subudhi S; Masia R; Drescher HK; Bartsch LM; Chicote ML; Chung RT; Gee DW; Witkowski ER; Bredella MA; Lauer GM; Corey KE; Dichtel LE
Growth Horm IGF Res; 2022 Aug; 65():101482. PubMed ID: 35780715
[TBL] [Abstract][Full Text] [Related]
34. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
[TBL] [Abstract][Full Text] [Related]
35. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
[TBL] [Abstract][Full Text] [Related]
37. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
[TBL] [Abstract][Full Text] [Related]
38. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.
De Luca-Johnson J; Wangensteen KJ; Hanson J; Krawitt E; Wilcox R
Dig Dis Sci; 2016 Sep; 61(9):2710-20. PubMed ID: 27262844
[TBL] [Abstract][Full Text] [Related]
39. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
[TBL] [Abstract][Full Text] [Related]
40. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
